Oncology CME

Medical Learning Institute, Inc.
Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG
April 30, 2020
Medical Learning Institute, Inc.
Improving Outcomes in Patients With Molecularly Altered NSCLC Through Broad Implementation of Precision Testing and Treatment: Latest Evidence and Practical Guidance in the Context of a Changing Targeted Therapy Landscape
Alexander Drilon, MD
April 30, 2020
Purdue University
Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Care
Hope S. Rugo, MD, FASCO
April 28, 2020
Medical Learning Institute, Inc.
Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists
Farnaz Dadmanesh, MD
April 6, 2020
Medical Learning Institute, Inc.
Multimodal Head and Neck Cancer Care Meets the Immunotherapy Era: A Look at the Changing Nature of Multidisciplinary Collaboration and Integrated Treatment Strategies
Barbara Burtness, MD
March 31, 2020
The Medical College of Wisconsin
State-of-the-Art Solutions for Myelofibrosis: The Intersection of JAK Inhibitors, Allogeneic Transplant, and Other Strategies for Patient Care
Prithviraj Bose, MD
March 23, 2020
Purdue University College of Pharmacy
Mapping the Pathways to Better Patient Outcomes in Prostate Cancer: Personal Insights and Guidance From the Patient CaseBook
William K. Oh, MD
March 18, 2020
Penn State College of Medicine
Raising the Bar With Innovative Therapy for Bladder Cancer: Insights on Clinical Decision-Making in the New Era of Care
Arjun Balar, MD
March 17, 2020
The Medical College of Wisconsin
Taking the Leap With CAR T: Opportunities for Improving Care and Optimizing Cell Therapy in Hematologic Cancers
Michael R. Bishop, MD
March 12, 2020
Penn State College of Medicine
Advancing Bladder Cancer Care With Novel Therapeutics: Where We Are Headed With Immunotherapy, Targeted, and Antibody Options
Arjun Balar, MD
March 10, 2020
Medical Learning Institute, Inc.
Evidence and Practicalities: Checkpoint Inhibition in Gastrointestinal Cancers—Translating Recent Advances in Gastric, Esophageal, and Colorectal Cancers
Manish A. Shah, MD
March 9, 2020
Medical Learning Institute, Inc.
Developing a Therapeutic Game Plan for the Management of Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook
Richard S. Finn, MD
March 6, 2020
Medical Learning Institute, Inc.
How I Think, How I Treat—Personal Insights on Current Practices and Evolving Standards of Care in Pancreatic Cancer: Expert Perspectives on Implementing State-of-the-Art Care in the Clinic
Johanna C. Bendell, MD
March 5, 2020
Medical Learning Institute, Inc.
Blazing the Therapeutic Management Trail of Biliary Cancers: Get Prepared for a New Era of Molecular- and Mutation-Driven Treatments
Milind Javle, MD
February 25, 2020
Medical Learning Institute, Inc.
Maximizing the Benefits and Minimizing the Risks of Cancer Immunotherapies in Everyday Oncology Practice: Need-to-Know Information and Practical Guidance for Oncology Nurses
Marianne Davies, DNP, ACNP, AOCNP
January 27, 2020
Medical Learning Institute, Inc.
The Expanding Playbook of Hepatocellular Carcinoma: Examining Scientific Data and Evidence With Your Multidisciplinary Team
Richard S. Finn, MD
January 13, 2020
Medical Learning Institute, Inc.
How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
Toni K. Choueiri, MD
December 31, 2019
Penn State College of Medicine
Expanding Options for Prophylaxis and Treatment of Acute and Chronic GVHD: Mapping the Path to Better Patient Outcomes in Post-Transplant Care
Miguel-Angel Perales, MD
December 31, 2019
Medical Learning Institute, Inc.
How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps
Andre H. Goy, MD
December 30, 2019
Medical Learning Institute, Inc.
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
Peter Schmid, FRCP, MD, PhD
December 30, 2019
Medical Learning Institute, Inc.
Enhancing Standards of Care for Patients With Biliary Tract Cancers: A Graphical Guide to Integrating a New Lineup of Targeted Therapies Into Practice
Milind Javle, MD
December 27, 2019
Medical Learning Institute, Inc.
MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions
Amit Singal, MD, MS
December 24, 2019
Medical Learning Institute, Inc.
Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science
Robin L. Jones, MD
December 19, 2019
Medical Learning Institute, Inc.
Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe
Evan J. Lipson, MD / Andrew Stolbach, MD, MPH
November 27, 2019
Penn State College of Medicine
Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors
Robert Coleman, MD
November 8, 2019
Medical Learning Institute, Inc.
Composing Personalized HCC Treatment Strategies: Insights on Harmonizing Patient Care With a Multidisciplinary Ensemble
Ghassan Abou-Alfa, MD, MBA
November 4, 2019
Medical Learning Institute, Inc.
Challenges, Controversies, and Opportunities in the Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases: Working Together to Improve Patient Outcomes
Kathryn Beal, MD / Sandip Patel, MD
November 4, 2019
Medical Learning Institute, Inc.
Identification, Triage, and Management of Immune-Related Adverse Effects in Patients With Cancer Presenting to the Emergency Department: Practical Guidance for Emergency Nurses
Sorayah Bourenane, MSN, RN, CNL / Marianne Davies, DNP, ACNP, AOCNP
October 29, 2019
Penn State College of Medicine
Driving Change in Multiple Myeloma: Updates on Novel Agent Classes and Next-Generation Therapeutics
Robert Z. Orlowski, MD, PhD
August 8, 2019
Medical Learning Institute, Inc.
Expanding Treatment Choices in Mesothelioma: Exploring the Promise of Tumor Treating Fields and Novel Systemic Approaches to Optimize Patient Outcomes
Charles B. Simone, MD, FACRO
July 29, 2019

Pages

Education Collections